NEW YORK (GenomeWeb News) – Compugen said today it will collaborate with Merck to predict and validate peptides that are likely to activate G-protein coupled receptors that Merck could use in its drug development programs.
 
The agreement, which Compugen said is its first such peptide collaboration, includes an option that would grant Merck exclusive worldwide licenses to develop and market these peptides.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.